Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib vs Rituximab for Cutaneous Sclerosis in Chronic GVHD
NCT01309997Phase 2Completed
- Start
- Mar 2011
- Primary completion
- Dec 2014
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in chronic graft-versus-host disease (cGVHD) comparing Imatinib with Rituximab (2 arms). Primary endpoint: Significant Clinical Response at 6 months. Started Mar 2011; status: completed.
02
Drugs
imatinibrituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT01309997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01309997.